Brief: Insmed Provides Clinical And Business Update
17/12/2025 21:03
Dec 17 (Reuters) - Insmed Inc INSM.O: INSMED PROVIDES CLINICAL AND BUSINESS UPDATE INSMED INC - PHASE 2B BIRCH STUDY OF BRENSOCATIB IN CRSSNP DID NOT MEET PRIMARY OR SECONDARY EFFICACY ENDPOINTS INSMED INC - DISCONTINUES CRSSNP PROGRAM INSMED INC - ACQUIRES PHASE 2 READY MONOCLONAL ANTIBODY FOR POTENTIAL RESPIRATORY AND IMMUNOLOGICAL & INFLAMMATORY INDICATIONS Source text: ID:nPnyHpg0a Further company coverage: INSM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insmed
See all newsAstera Labs, CoreWeave and others rise after Nasdaq-100 inclusion
U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle
U.S. RESEARCH ROUNDUP- Adobe, Allstate, Teleflex
Brief: Insmed Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings